Press Releases from Academic Institutions and Companies

The press releases on this page were submitted by institutions and companies and are being shared as a service to reporters covering the annual meeting. Each press release was written solely by the submitting institution or company. While ASH staff have confirmed the embargo times and abstract numbers, the Society is not responsible for the accuracy of the content.

ASH Annual Meeting Embargo Policy

The media as well as corporations and institutions issuing press releases are required to abide by the embargo policies governing the Society's annual meeting.

Press Releases

Antibody drug sharply reduces risk of severe chronic graft-versus-host disease in patients undergoing allogeneic stem cell transplant, trial shows

Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial

Patients with a common form of acute myeloid leukemia report better quality of life when treatment includes new drug quizartinib

Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL)

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine Tip Sheet

SymBio Announces Positive Preliminary Data from Ongoing Phase 2a Study of Intravenous Brincidofovir in Immunocompromised Patients With Adenovirus Infection in an Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Transdermal Curcumin Yields Promising Data for Sickle Cell Sufferers Presented at Annual American Society of Hematology Conference in San Diego, California

Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial

Research Alert: New Sylvester Cancer Study Provides Insight Into Underlying Gene Mutations in Myelodysplastic Syndromes

Combination immunotherapy produces high response rate in early results of Sylvester trial targeting high-risk follicular lymphoma

Cell Therapy Appears Safe and Effective for Lymphoma in Remission

Phase 1 data from a CD19-specific third generation CAR T cell study supports use of BioOra’s automated manufacture for phase 2 trial